^
Association details:
| Biomarker: | FGFR3 Y373C |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
INTERIM RESULTS FROM A PHASE 1B CLINICAL TRIAL EVALUATING TOLERABILITY AND ACTIVITY OF FGFR INHIBITION IN LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA (UTUC)
Published date:
04/09/2022
Excerpt:
We initiated a biomarker-informed preoperative study of infigratinib in patients with localized UTUC. 4 of 9 (44%) patients had a response with tumor reduction (range 25-83%); all responders had FGFR3 mutations. Infigratinib shows substantial activity in patients with localized UTUC bearing FGFR3 mutations...
DOI:
https://doi.org/10.1097/JU.0000000000002669.10
Trial ID:
Source:
Title:
Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations
Excerpt:
A decrease in FGFR3 mutations with BGJ398 treatment appeared to correlate with a longer time on study and a greater percentage decrease in tumor size from baseline...An analysis of clinical outcome limited to patients with documented activating mutations in FGFR3 (S249C, R248C, Y375C and Y373C) yields a confirmed response rate of 28.6% (16 of 56 patients); including unconfirmed responses, the response rate rises further to 42.9% (24 of 56 patients).
DOI:
10.1158/2159-8290.CD-18-0229
